• LAST PRICE
    3.2900
  • TODAY'S CHANGE (%)
    Trending Up0.0300 (0.9202%)
  • Bid / Lots
    3.2800/ 9
  • Ask / Lots
    3.3000/ 2
  • Open / Previous Close
    3.3431 / 3.2600
  • Day Range
    Low 3.2800
    High 3.3708
  • 52 Week Range
    Low 2.9640
    High 29.0000
  • Volume
    21,465
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 3.26
TimeVolumeAYTU
09:44 ET1003.3431
09:51 ET1003.3029
09:57 ET7923.3523
10:00 ET4503.3589
10:02 ET1003.2801
10:15 ET2503.3381
10:24 ET6503.29
10:27 ET4003.3348
10:29 ET14003.3117
10:31 ET34003.31
10:33 ET1503.29
10:36 ET8003.3106
10:38 ET13003.3708
10:40 ET1003.3452
10:47 ET1003.33
10:49 ET1003.3653
10:51 ET2003.33
10:54 ET1003.325
10:58 ET1003.3386
11:03 ET1003.3
11:05 ET4893.3
11:07 ET19003.3
11:09 ET1113.28
11:20 ET2923.2819
11:27 ET2503.28
11:30 ET4003.305
11:41 ET6703.3228
11:48 ET7453.3
11:56 ET7503.3075
11:57 ET8053.3
11:59 ET2503.3025
12:03 ET1253.3051
12:10 ET14003.3
12:12 ET1003.28
12:14 ET1443.2886
12:32 ET4003.29
12:35 ET1303.29
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesAYTU
Aytu Biopharma Inc
10.2M
-0.3x
---
United StatesKALY
Kali Inc
1.0K
0.0x
---
United StatesIPAH
Interpharm Holdings Inc
70.0
0.0x
---
United StatesPXYN
Praxsyn Corp
790.0
0.0x
---
United StatesCHME
China Medicine Corp
78.0K
0.0x
---
United StatesDERM
Journey Medical Corp
26.1M
-0.8x
---
As of 2023-02-02

Company Information

Aytu BioPharma, Inc. is a pharmaceutical company. The Company is focused on commercializing therapeutics and consumer health products and developing therapeutics for rare pediatric-onset or difficult-to-treat diseases. It manufactures its products for the treatment of attention deficit hyperactivity disorder (ADHD) at its manufacturing facilities and uses third party manufacturers for its other prescription and consumer health products. The Company operates through two business segments: BioPharma and Consumer Health. The BioPharma segment consists of prescription pharmaceutical products (the Rx Portfolio). The Consumer Health segment consists of various consumer healthcare products (the Consumer Health Portfolio). The Company also has two product candidates in development, AR101 (enzastaurin) for the treatment of vascular Ehlers-Danlos Syndrome (VEDS) and Healight (endotracheal ultraviolet light catheter) for the treatment of severe, difficult-to-treat respiratory infections.

Contact Information

Headquarters
373 Inverness Pkwy Ste 206ENGLEWOOD, CO, United States 80112-5898
Phone
720-437-6580
Fax
302-636-5454

Executives

Chairman of the Board, Chief Executive Officer
Joshua Disbrow
Chief Financial Officer
Mark Oki
Chief Operating Officer
Christopher Brooke
Independent Director
Carl Dockery
Independent Director
John Donofrio

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$10.2M
Revenue (TTM)
$102.4M
Shares Outstanding
3.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-0.42
EPS
$-12.13
Book Value
$1.19
P/E Ratio
-0.3x
Price/Sales (TTM)
0.1
Price/Cash Flow (TTM)
---
Operating Margin
-83.32%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.